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ABSTRACT
Generalized anxiety disorder is a complex psychiatric syndrome. Current understanding on the epidemiological risk
factors, genetic vulnerability and neurobiology of the GAD is beginning to unfold the complexities behind this disorder.
This narrative review has attempted to put together the recent advances in the area of GAD research with intent to
identify the gaps requiring further research.

INTRODUCTION

anxiety disorders in US adolescent population is 31.9%.
The life time prevalence of GAD is reported to be 2.02%.
4The prevalence of GAD increases consistently with
age. It is reported to be 1% in the age group of 13 to
14 years of age while3 % in the age group of 17 to 18
years.4The prevalence of GAD in the US population have
been reported to range between 2 to 9% across all age
groups.5 The prevalence of GAD is more in females
(3%) as compare to males (1.5%).4The twelve month
prevalence of GAD in geriatric population of US has
been reported to be 2.8%.

Anxiety is a great modern day plague. It has reached
a pandemic proportion. The concept of Anxiety disorders,
as explained in the psychiatry nomenclature, has various
descriptions. The focus of classification is on physical
manifestation of psychological symptoms. This has
steamed from the behavioral model of psychology. One
of the key proponents of this conceptualization was Sir
William James (1842-1910), famous American
psychologist and philosopher, who described the
relationship between body and mind. The classification
system has undergone periodic revision over the course
of years whence the description of symptoms and their
numbers, required to make a diagnosis, has changed.
The neurobiological understanding of the disorder has
also changed over the course of time. This review will
focus on the epidemiological, genetic and radiological
underpinning of the GAD.

The twelve month prevalence of GAD in the European
population has been reported to be 2%.6The one month
prevalence of GAD is 4.1% in Sweden.7 Most of the
GAD patients in European Union (EU) present to the
primary health centers.6 Many of these cases remain
unrecognized. A study from EU reported that almost
half of the patients with GAD were left un-diagnosed
when consulting their general practitioners. 8Similarly,
in Asian countries, like China the one month prevalence
of GAD ranges from 2% to 2.9%.9 The life time prevalence
of GAD in Hong Kong range from 5% to 10%.10 A study
done on adolescents in India showed the prevalence
of GAD to be 19%.11The general population based
survey from Iran reports the prevalence of GAD to be
0.73%.12 In Pakistan the prevalence of anxiety disorders
in a semi urban population was found to be 30%. 13

Generalized anxiety disorder (GAD) is characterized by
persistent, pervasive and uncontrollable state of worry
which is disproportionate to its source and lasts for
at least six months.1(Table 1)
Prevalence of GAD:
The prevalence of GAD is varies from different studies
in different populations. The use of diagnostic
conventions, whether the ICD - 10 or DSM IV diagnostic
criteria, also contributes to the variability of
estimates.2According to a recent NHANES data base
the prevalence of GAD in the United States(US) children
is 0.7%.3 According to National Co-morbidityAdolescent
Supplement Study the life time prevalence of various
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Various factors which affect the pattern of 'repetitive
thoughts' of 'worrying' nature has important bearing on
conversion of physiological anxiety to pathological anxiety
and hence GAD.14Age is an important epidemiological

22

VOL.

8(1) JAN - MAR

2013

studies tried to find out the cost of prevalence i.e.
finding one year cost of GAD that includes direct and
indirect cost. Another type of cost estimation was from
cohort studies which found out cost from incident cases.
Another important variability in the cost of GAD coming
out from different studies is because all studies used
direct cost but very few studies used direct as well as
indirect cost of GAD.

variable and risk factor for some disorders; one study
showed a declining patterns of anxiety with increasing
age .15 Prevalence of GAD was found to be highest in
the age group of 15 to 45 years.16 GAD is also reported
to be higher among women as compare to men.16
Although marriage is a protective factor against mental
illnesses, a cross section, community based study from
Pakistan found a higher prevalence of psychiatric
morbidity (including GAD) in a sub-sample of married
females.17, 18

In one study the total one year cost of different anxiety
disorders in US was reported to be 46,551 million
USDs out of which 10,748 million USDs was the direct
cost while 35,436 USDs was the indirect cost.26 The
prevalence of GAD among these patients was found to
be 40%.26 With multiple regression analysis, looking to
estimate the individual cost of GAD, figure came to be
42,300 billion USDs which was around 1,542$ per
patient.27 This cost includes direct as well as indirect
cost adjusted for many other independent variables.
GAD is a condition which is frequently found co-morbid
with other disorders. The co morbidity increases the
cost of both the conditions i.e. GAD as well as the
co-morbidity as has been demonstrated in migraine.28

Alcohol abuse and dependence is also known to
increases the incidence of GAD.19 Benzodiazepines are
normally used to treat GAD. 2 0 However, taking
benzodiazepines without prescription and easy availability
(over the counter sales) results in addiction.20 Individuals
(develop dependence and) experience withdrawal
anxiety if they do not get benzodiazepines.20 Therefore
these drugs paradoxically become the cause of GAD.20
Low education is a known risk factor for many mental
disorders.21 Psychiatric co-morbidities like depression,
borderline personality disorder and schizotypal personality
disorder have been reported to be associated with
GAD.19, 21 Mood disorders, like major depressive disorder
(MDD) are co-morbid with GAD. This is explained by a
shared etiology for both the disorders.21 Romantic
relationships have paradoxical association with anxiety.22
It was found that dating decreases anxiety but disturbed
relationship with the partner increases anxiety and may
predispose a person to GAD.22 Presence of regular work
opportunity has been reported to be protective against
GAD.23 Socio-economic status has an effect on GAD.
However the nature of this effect is inconclusive from
the previous studies in Pakistan.23Pathological Internet
usage also predisposes a person to GAD.24 Loss of
spouse predisposes a person to GAD.17GAD, like most
mental disorders, is associated with significant morbidity.
One way to quantify the burden of disease is to quantify
the cost of care for individuals and the society.

New Genetic findings related to GAD:
Genetic makeup of a person has been reported to be
responsible for giving different responses to the drug
treatment. This has been demonstrated in a recent
study in which the response to venlafaxine was lower
in the group having a La/La+G/G or La/La+G/A
genotype.29 An important gene which has been recently
studied through knockout studies of mice is GABA and
its role of y2-/- versus y2+/- genes. 30 It was
demonstrated that the vulnerability of mice to anxiety
changed after manipulating these genes through
knockout techniques.30 What is the role of these genes
in human beings and their anxiety status needs to be
evaluated.

Cost of GAD Care:

In a pilot study involving different metabolites which
include L-amygdala Cr, L Amygdala ml (L+R), Rhippocampus Glx, OFC Cr and OFC NAA have been
reported to affect the GAD status of a person.31Authors
concluded that all genes directly or indirectly effecting
these metabolites which have an impact on different
anxiety disorders including GAD.31

GAD puts a lot of cost on the society as direct health
care cost as well as cost due to productivity losses.25
The direct health care cost is large because studies
have shown that in developing countries patients with
different types of anxiety are high utilizes of the health
systems for curing their mental illness.26 The cost of
GAD reported varies depending on a number of factors
important ones being the country in which the study is
being done and the methodology of the study. The
methodology adopted for costing of GAD varies
significantly between different studies. Some of the
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The effect of genes that include 5-HTTLPR,
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COMTval158met, and BDNFval66met on the treatment
outcome of social anxiety was studied through a
randomized control trial where Internet-based cognitive
behavior therapy (ICBT) was compared with cognitive
behavioral group therapy for (CBGT).32 No significant
effect was found of these genes on the treatment
outcomes. The effect of antidepressants on the treat
GAD is hypothesized to be effected by variant rs4680
of COMT gene. In one study the effect of this particular
variant of COMT gene on the anxiety status of a people
in the European American sub sample was positively
associated. These finding can be confirmed through
further studies.33

dorsomedial prefrontal cortex increased, which can be
detected through MRI.40 Another important parameter
raised in GAD is N-acetylaspartate/creatine ratios in
dorsolateral prefrontal cortex and it is assessed using
proton magnetic resonance spectroscopy.41 This ratio
was 16.5% higher in one study with a total sample size
of 30 individuals. 41 GAD patients were found to have
increased apparent diffusion coefficient in right parietal
cortex and right splenium using a diffusion weighted
magnetic resonance imaging.42 More focused work
where the functional connection of different nuclei of
amygdale in GAD patients' needs to be was evaluated.43
GAD patients were found to have problems

If the parents are suffering from a particular anxiety
disorder, the risk of children for suffering from different
anxiety disorders increases. The precise cause of
excessive vulnerability, whether genetic or environmental,
needs to be separated out in further research.34A
Meta-analysis done to find out the effect of genetic
versus a (shared) environment in separation anxiety
disorder concluded both genetic and environmental
effect are present.35 Since there are important conceptual
differences between GAD and separation anxiety
disorders, we cannot directly generalize the findings of
this meta-analysis to GAD patients.

in connection of different nuclei of amygdale.43 Some
studies have evaluated this using resting stage functional
magnetic resonance imaging. Further it was found that
as the severity of GAD increases, the problem with
functional connection among the different nuclei of
amygdale also increased.43Centro medial and basolateral
amygdala was identified as the most problem area in
GAD patients.43
Treatment of GAD:
The evidence based treatment of GAD can be
dichotomized in to psychological and
psychopharmacological intervention. In following sections
we will present a brief overview of the treatment. Those
interested in knowing the further details are advises to
consult the cited reference material.

Neuroimaging and GAD:
Different brain areas are involved in the neurobiology
of GAD. Bed of nucleus striaterminalis, the insula,
anterior orbitofrontal cortex, hippocampus, anterior
cingulated cortex and amygdala are important regions
out of many others.36, 37 In one study the volumes of
amydala was reported to have increased in children
and adolescents living with a case of GAD.38 Stressful
response in GAD results in decreased activity in amygdale
and increased activity in bed of nucleus stria terminalis.36
These decreased and increased responses were picked
through fMRI.36 This study generated the hypothesis of
decreased activity in amygdale and increased activity
in bed nucleus of striaterminalis.36

Psychological treatments While the general relaxation
technique, breathing exercises and guided imagery are
indicated in most cases of GAD, there are various forms
of psychological treatment which are specific for therapies
include client centered, supportive-expressive and
rational emotive therapies. 44
It is recommended that psychological intervention be
started first before going for pharmacotherapy. However,
in a developing country like Pakistan, where on one
hand there is a dearth of trained clinical psychologists
and the prevalence of GAD is greater than many other
countries bringing the recommendation of trying the
psychotherapy before pharmacotherapy becomes a real
challenge. Further, the problem is complicated as very
few of the psychotherapies are culturally adapted for
the indigenous population. Therefore completing the
bio-psychosocial model for the treatment of GAD patients
becomes a real challenge for the practicing physicians.

It was reported that young patients with GAD had an
increase in the volume of gray matter in right precuneus
and right precentralgyrus while the gray matter in the
posterior cingulate and left orbital gyrus is decreased.39
Further, in the same study it was reported that in the
GAD patients, the white matter is decreased in superior
frontal and left medial gyrus whereas it is increased in
left inferior temporal gyrus.39 These comparisons were
elicited using voxel-based morphometry.39 In a sample
of sixteen women it was found that the volume of
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Table 1
ICD 10 Criteria for Generalized anxiety disorder (WHO ICD 10 criteria for research)
a. A period of at least six months with prominent tension, worry and feelings of apprehension, about
every-day events and problems.
b. At least four symptoms out of the following list of items must be present, of which at least one from
items(1) to (4).
Autonomic arousal symptoms
(1) Palpitations or pounding heart, or accelerated heart rate.
(2) Sweating.
(3) Trembling or shaking.
(4) Dry mouth (not due to medication or dehydration).
Symptoms concerning chest and abdomen
(5) Difficulty breathing.
(6) Feeling of choking.
(7) Chest pain or discomfort.
(8) Nausea or abdominal distress (e.g. churning in stomach). Symptoms concerning brain and mind
(9) Feeling dizzy, unsteady, faint or light-headed.
(10) Feelings that objects are unreal (derealization), or that one's self is distant or "not really here" (depersonalization).
(11) Fear of losing control, going crazy, or passing out.
(12) Fear of dying.
General symptoms
(13) Hot flushes or cold chills.
(14) Numbness or tingling sensations.
Symptoms of tension
(15) Muscle tension or aches and pains.
(16) Restlessness and inability to relax.
(17) Feeling keyed up, or on edge, or of mental tension.
(18) A sensation of a lump in the throat, or difficulty with swallowing.
Other non-specific symptoms
(19) Exaggerated response to minor surprises or being startled. (20) Difficulty in concentrating, or mind going blank,
because of worrying or anxiety.
(21) Persistent irritability.
(22) Difficulty getting to sleep because of worrying.
c. The disorder does not meet the criteria for panic disorder, phobic anxiety disorders,
obsessive-compulsive disorder or hypochondriacal disorder
d. Most commonly used exclusion criteria: not sustained by a physical disorder, such as hyperthyroidism,
an organic mental disorder or psychoactive substance-related disorder, such as excess consumption of
amphetamine-like substances, or withdrawal from benzodiazepines.
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Drug treatment:
The drugs prescribed for the GAD patients include
selective serotonin reuptake inhibitors, selective
norepinephrine reuptake inhibitors, tricyclic
anti-depressant, benzodiazepines and sometimes even
low dose of anti-psychotics.44 SSRIs are considered to
be the first line of treatment for GAD because of their
efficacy and tolerability. However they have the propensity
to exacerbate anxiety in the early stages of the treatment.
Therefore it is best to start with low dose and titrate it
to recommended levels. Benzodiazepines are the other
drugs which are most frequently prescribed. Their side
effects include tremors, nausea, headache, agitation
and sleep disturbance.44 Tolerance and dependence
have been reported with more than two weeks of
benzodiazepines therapy. Due to the potential of
dependence, benzodiazepines are not recommended
as the first line agents.44 Non-benzodiazepines anxiolytics,
like Buspirone, also established efficacy in the
management of GAD.44

5.

6.
7.

8.

CONCLUSION

9.

GAD is a complex psychiatric disorder with high
prevalence rates. There are underlying genetic risk
factors which have been focus of research in recent
times. A substantial body of literature examines the
neurobiological changes associated with the GAD. While
effective therapies for the management of GAD exist
their provision in the resource-constrained settings is
a great challenge. More research is needed in order to
understand the epidemiological risk factors and
neurobiological underpinning of the GAD.
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